EWPI Emerging World Pharma Inc (CE)

Emerging Growth Pharma Inc. (PINKSHEETS: EWPI), an investor in generic based pharmaceutical companies manufacturing within developing nations, is pleased to introduce the corporation's management line up.

President: Brandon Keks

Most recently Mr. Keks acted as the Director of Operations and Administration with Global Pharma Inc. (Canada). In this role, Mr. Keks worked closely with the President/CEO to oversee the day-to-day activities of the company's international organizations. Also working in partnership with the International Managing Directors, Mr. Keks focused on the operational systems and procedures required to accomplish the company's mission and goals in the marketplace.

Director: Dr. William G. Middleton BSc, MD, FRCS(C)

Dr. Middleton is a board certified surgeon who has been practicing cosmetic surgery since 1985. He is internationally recognized for his surgical skills and artistry. Dr. Middleton is a professor at the University of Toronto, Faculty of Medicine. Dr. Middleton spent 8 years at the University of Western Ontario where he obtained his Bachelor of Science and Medical Degrees. Dr. Middleton is a member of the Fellow of the Royal College of Surgeons of Canada Board Certified: American Board of Medical Specialties in Otolaryngology.

Director: Mr. Roy Duodo-Sarpong

Mr. Duodo-Sarpong brings more than 20 years of industrial, information and management consulting leadership experience into our company. Most recently Mr. Duodo-Sarpong has been in the position of Regional Project Director for Africa for Business Development with African Global Pharma (Ghana) Limited. Previously, Mr. Duodo-Sarpong served as a Project Management Director for NORTEL Networks where he was responsible for all aspects of the global IT organization including the implementation of a series of new applications and processes for the company's network configuration and solutions businesses in Asia Pacific -- Australia, Malaysia, Taiwan, Singapore and Beijing -- China.

"I strongly believe that the expertise and experience this selective group of individuals brings will lead Emerging World Pharma to unparalleled opportunities in these markets in 2010," stated company president Brandon Keks.

For more information on Emerging World Pharma please visit our website at http://emergingpharma.com/

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com